logo-loader
viewhVIVO PLC

hVIVO lands two new contracts worth £9mln

The specialist in human disease models said it is in talks with pharmaceutical companies over further deals

petrie dish
An order has come in for a further two respiratory syncytial virus human challenge studies

hVIVO PLC (AIM:HVO), a specialist in human disease models, said it is in talks with pharmaceutical companies over further deals after landing new contracts worth £9mln.

Updating the market, it said it will provide an unnamed “leading global biopharmaceutical company” with two respiratory syncytial virus (RSV) human challenge studies. This follows last month’s £11.9mln RSV agreement.

Contagious, respiratory syncytial virus causes the common cold, for which there is no effective cure.

Revenue impact next year

The revenue impact of the latest deal will be felt mainly next year.

“The recent significant new contract wins reinforce our leading position in human disease models based upon viral and allergen challenge and are a testament to our industry leading RSV-human challenge model,” said chairman, Dr Trevor Phillips.

“We have the strongest sales pipeline we have had for several years.

“We remain actively engaged in several discussions with other pharmaceutical companies for contracting studies across our current challenge portfolio, including allergen, asthma, human rhinovirus, influenza and RSV.”

High levels of demand

Phillips said hVIVO continued to experience “high levels of interest” from global pharma companies interested in new challenge models for RSV, asthma and chronic obstructive pulmonary disease.

“With the significant demand for our services across the entire portfolio, we expect to convert a growing number of these opportunities into contracts that will further validate our service offerings and enhance our revenue in 2019 and beyond," he added.

In a separate announcement, hVIVO said former chairman Jaime Ellertson is leaving the board with immediate effect.

The shares rose 10% at 64.60p, valuing the business at just shy of £51mln.

--- Adds share price ---

 

Quick facts: hVIVO PLC

Price: - -

LSE:HVO
Market: LSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...

on 10/12/19

2 min read